Table 2.
Mean changes in weight and laboratory values
| OLZ LAI 150 (N = 140) Mean (SD) | OLZ LAI 405 (N = 318) Mean (SD) | OLZ LAI 300 (N = 141) Mean (SD) | R-Square | Regression Slope | Regression p-value | Jonckheere-Terpstra p-value | Effect Sizes | |||
|---|---|---|---|---|---|---|---|---|---|---|
| High vs. Low (95% C.I.) | Medium vs. Low (95% C.I.) | High vs. Medium (95% C.I.) | ||||||||
| Weight (kg) | 0.67 (4.38) | 0.89 (3.87) | 1.70 (4.14) | 0.0086 | 0.10 | .024 | .034 | 0.264 | 0.063 | 0.201 |
| in lbs: | 1.47 (9.64) | 1.96 (8.51) | 3.74 (9.11) | |||||||
| Fasting glucose (mmol/L) | 0.14 (1.36) | 0.17 (1.29) | 0.22 (1.19) | 0.0005 | 0.01 | .642 | .092 | 0.049 | 0.016 | 0.033 |
| in mg/dL: | 2.52 (24.50) | 3.06 (23.24) | 3.96 (21.44) | |||||||
| Fasting HDL (mmol/L) | -0.00 (0.22) | 0.00 (0.24) | -0.05 (0.24) | 0.0064 | -0.01 | .094 | .215 | 0.196 | 0.022 | 0.218 |
| in mg/dL: | -0.00 (8.49) | 0.00 (9.27) | -1.93 (9.27) | |||||||
| Fasting LDL (mmol/L) | -0.04 (0.57) | -0.07 (0.64) | 0.02 (0.73) | 0.0015 | 0.01 | .423 | .169 | 0.078 | 0.041 | 0.119 |
| in mg/dL: | -1.54 (22.01) | -2.70 (24.71) | 0.77 (28.19) | |||||||
| Fasting total cholesterol (mmol/L) | -0.12 (0.65) | -0.07 (0.73) | 0.01 (0.78) | 0.0037 | 0.01 | .199 | .240 | 0.165 | 0.065 | 0.100 |
| in mg/dL: | -4.63 (25.10) | -2.70 (28.19) | 0.39 (30.12) | |||||||
| Fasting triglycerides (mmol/L) | -0.18 (1.84) | -0.03 (1.23) | 0.03 (1.19) | 0.0022 | 0.02 | .324 | .958 | 0.147 | 0.107 | 0.039 |
| in mg/dL: | -15.93 (162.83) | -2.65 (108.85) | 2.65 (105.31) | |||||||
| Prolactin (μg/L): | ||||||||||
| All patients | -5.61 (12.49) | -2.76 (19.02) | 3.58 (33.78) | 0.0209 | 0.87 | .001 | <.001 | 0.410 | 0.127 | 0.283 |
| Females | -8.27 (16.1) | -2.86 (30.31) | 4.33 (23.16) | 0.0294 | 1.16 | .026 | <.001 | 0.493 | 0.212 | 0.281 |
| Males | -3.88 (9.17) | -2.72 (9.65) | 3.16 (38.56) | 0.0159 | 0.70 | .025 | .018 | 0.347 | 0.047 | 0.300 |
Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141); HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol.